These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 25741561)

  • 21. Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage II and stage III breast cancer.
    Petrarca CR; Brunetto AT; Duval V; Brondani A; Carvalho GP; Garicochea B
    Clin Breast Cancer; 2011 Apr; 11(2):129-34. PubMed ID: 21569999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel targets for triple-negative breast cancer.
    Carey LA
    Clin Adv Hematol Oncol; 2011 Sep; 9(9):678-80. PubMed ID: 22402512
    [No Abstract]   [Full Text] [Related]  

  • 23. Primary pure signet cell carcinoma of the breast: a case report and review of the literature.
    Karabagli P; Kilic H
    Breast Cancer; 2013 Oct; 20(4):363-6. PubMed ID: 20556557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Challenges for future breast cancer trials.
    Lawrence G
    Oncology (Williston Park); 1996 Nov; 10(11):1610. PubMed ID: 8953582
    [No Abstract]   [Full Text] [Related]  

  • 25. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.
    Houssami N; Macaskill P; von Minckwitz G; Marinovich ML; Mamounas E
    Eur J Cancer; 2012 Dec; 48(18):3342-54. PubMed ID: 22766518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pathomorphologic patient selection for systemic therapy].
    Olszewski WP; Chmielik E; Ryś J
    Pol J Pathol; 2011 Dec; 62(4 Suppl 4):s28-33. PubMed ID: 22693730
    [No Abstract]   [Full Text] [Related]  

  • 27. Resistin expression in breast cancer tissue as a marker of prognosis and hormone therapy stratification.
    Lee YC; Chen YJ; Wu CC; Lo S; Hou MF; Yuan SS
    Gynecol Oncol; 2012 Jun; 125(3):742-50. PubMed ID: 22370603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum tumor markers in patients with breast cancer.
    Lumachi F; Basso SM
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):921-31. PubMed ID: 15485325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decision tree and paradigms of primary breast cancer: changes elicited by preoperative therapy.
    Toi M; Bando H; Saji S
    Med Sci Monit; 2003 May; 9(5):RA90-5. PubMed ID: 12761467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
    Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
    J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Innovative biomarker development for personalized medicine in breast cancer care.
    Zografos GC; Roukos DH
    Biomark Med; 2011 Feb; 5(1):73-8. PubMed ID: 21319967
    [No Abstract]   [Full Text] [Related]  

  • 32. Triple-negative breast cancers: unique clinical presentations and outcomes.
    Billar JA; Dueck AC; Stucky CC; Gray RJ; Wasif N; Northfelt DW; McCullough AE; Pockaj BA
    Ann Surg Oncol; 2010 Oct; 17 Suppl 3():384-90. PubMed ID: 20853062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pitfalls in outcome prediction of breast cancer.
    Rakha EA
    J Clin Pathol; 2013 Jun; 66(6):458-64. PubMed ID: 23618694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical trials in metastatic breast cancer to bone: past--present--future.
    Body JJ
    Can J Oncol; 1995 Dec; 5 Suppl 1():16-27. PubMed ID: 8853520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathological definition of triple negative breast cancer.
    Viale G; Bottiglieri L
    Eur J Cancer; 2009 Sep; 45 Suppl 1():5-10. PubMed ID: 19775600
    [No Abstract]   [Full Text] [Related]  

  • 36. [Prognostic factors in breast cancer and their consequences for therapeutic decisions].
    Graeff H; Jänicke F
    Chirurg; 1992 Jun; 63(6):461-8. PubMed ID: 1643982
    [No Abstract]   [Full Text] [Related]  

  • 37. Emerging biomarkers in breast cancer care.
    Napieralski R; Brünner N; Mengele K; Schmitt M
    Biomark Med; 2010 Aug; 4(4):505-22. PubMed ID: 20701440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer.
    Shibuta K; Ueo H; Furusawa H; Komaki K; Rai Y; Sagara Y; Kamada Y; Tamaki N
    Breast Cancer; 2011 Oct; 18(4):292-8. PubMed ID: 20571962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A deleterious BRCA1 mutation in a young Pakistani woman with metaplastic breast carcinoma.
    Rashid MU; Shah MA; Azhar R; Syed AA; Amin A; Hamann U
    Pathol Res Pract; 2011 Sep; 207(9):583-6. PubMed ID: 21723046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Breast cancer and molecular markers].
    Ishioka C
    Gan To Kagaku Ryoho; 2008 Aug; 35(8):1261-8. PubMed ID: 18701834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.